Literature DB >> 15261141

Chk1 is haploinsufficient for multiple functions critical to tumor suppression.

Michael H Lam1, Qinghua Liu, Stephen J Elledge, Jeffrey M Rosen.   

Abstract

The haploinsufficient tumor suppressor Chk1 is essential for embryonic cells, but the consequences of Chk1 loss in adult tissues are unknown. Using conditional Chk1 mice, we find that proliferating mammary cells lacking Chk1 undergo apoptosis leading to developmental defects. Conditional Chk1 heterozygosity increased the number of S phase cells and caused spontaneous DNA damage. Chk1+/- epithelia also exhibit a miscoordinated cell cycle in which S phase cells display an early mitotic phenotype. These cells maintain high levels of Cdc25A, which can promote inappropriate cell cycle transitions. Thus, Chk1 heterozygosity results in three distinct haploinsufficient phenotypes that can contribute to tumorigenesis: inappropriate S phase entry, accumulation of DNA damage during replication, and failure to restrain mitotic entry.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15261141     DOI: 10.1016/j.ccr.2004.06.015

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  119 in total

1.  Thresholds of replication stress signaling in cancer development and treatment.

Authors:  Jiri Bartek; Martin Mistrik; Jirina Bartkova
Journal:  Nat Struct Mol Biol       Date:  2012-01-05       Impact factor: 15.369

2.  Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress.

Authors:  Rene Rodriguez; Mark Meuth
Journal:  Mol Biol Cell       Date:  2005-11-09       Impact factor: 4.138

3.  p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.

Authors:  H Christian Reinhardt; Aaron S Aslanian; Jacqueline A Lees; Michael B Yaffe
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

4.  RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma.

Authors:  Kristina A Cole; Jonathan Huggins; Michael Laquaglia; Chase E Hulderman; Mike R Russell; Kristopher Bosse; Sharon J Diskin; Edward F Attiyeh; Rachel Sennett; Geoffrey Norris; Marci Laudenslager; Andrew C Wood; Patrick A Mayes; Jayanti Jagannathan; Cynthia Winter; Yael P Mosse; John M Maris
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-02       Impact factor: 11.205

5.  Cross-talk between Chk1 and Chk2 in double-mutant thymocytes.

Authors:  Kathrin Zaugg; Yu-Wen Su; Patrick T Reilly; Yasmin Moolani; Carol C Cheung; Razquallah Hakem; Atsushi Hirao; Qinghua Liu; Stephen J Elledge; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-26       Impact factor: 11.205

Review 6.  In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets.

Authors:  Hiroaki Kiyokawa; Dipankar Ray
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

7.  Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.

Authors:  Elda Grabocka; Yuliya Pylayeva-Gupta; Mathew J K Jones; Veronica Lubkov; Eyoel Yemanaberhan; Laura Taylor; Hao Hsuan Jeng; Dafna Bar-Sagi
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

8.  HUS1 regulates in vivo responses to genotoxic chemotherapies.

Authors:  G Balmus; P X Lim; A Oswald; K R Hume; A Cassano; J Pierre; A Hill; W Huang; A August; T Stokol; T Southard; R S Weiss
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

9.  Quercetin enhances the effects of 5-fluorouracil-mediated growth inhibition and apoptosis of esophageal cancer cells by inhibiting NF-κB.

Authors:  Lu Chuang-Xin; Wang Wen-Yu; Cui Yao; Li Xiao-Yan; Zhou Yun
Journal:  Oncol Lett       Date:  2012-07-27       Impact factor: 2.967

10.  The combined status of ATM and p53 link tumor development with therapeutic response.

Authors:  Hai Jiang; H Christian Reinhardt; Jirina Bartkova; Johanna Tommiska; Carl Blomqvist; Heli Nevanlinna; Jiri Bartek; Michael B Yaffe; Michael T Hemann
Journal:  Genes Dev       Date:  2009-07-16       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.